Cellectar Biosciences, Inc.

Contributing Author

Recent Articles by Cellectar Biosciences, Inc.

Mar-04	Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates CLRB +8.21% GlobeNewswire
Feb-25	Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 CLRB GlobeNewswire
Feb-17	Cellectar Biosciences Expands Global Intellectual Property Estate CLRB -5.17% GlobeNewswire
Jan-09	Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference CLRB -6.95% GlobeNewswire
Dec-16	Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies CLRB GlobeNewswire
Nov-13	Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update CLRB -18.00% GlobeNewswire
Nov-06	Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025 CLRB GlobeNewswire
Oct-27	Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma CLRB -10.25% GlobeNewswire
Oct-14	Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research CLRB GlobeNewswire
Oct-07	Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million CLRB -16.86% GlobeNewswire
Oct-06	Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM) CLRB +6.75% GlobeNewswire
Sep-30	Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer CLRB GlobeNewswire
Sep-24	Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC) CLRB +11.15% GlobeNewswire
Sep-11	Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225 CLRB +5.60% GlobeNewswire
Sep-09	Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit CLRB +5.17% GlobeNewswire
Sep-05	Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September CLRB GlobeNewswire
Sep-03	Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research CLRB GlobeNewswire
Aug-27	Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer CLRB GlobeNewswire
Aug-14	Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update CLRB GlobeNewswire
Aug-07	Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025 CLRB GlobeNewswire
Jul-02	Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option CLRB GlobeNewswire
Jul-01	Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering CLRB -31.65% GlobeNewswire
Jun-26	Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement CLRB -7.05% GlobeNewswire
Jun-24	Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC) CLRB +8.57% GlobeNewswire
Jun-18	Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split CLRB -20.16% CLRB GlobeNewswire
Jun-11	Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma CLRB +16.64% GlobeNewswire
Jun-05	Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules CLRB -11.61% GlobeNewswire
Jun-04	Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM) CLRB +66.32% GlobeNewswire
May-13	Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update CLRB -9.13% GlobeNewswire
May-07	Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025 CLRB GlobeNewswire

Cellectar Biosciences, Inc.

Recent Articles by Cellectar Biosciences, Inc.

Upgrade your FINVIZ experience